[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemophagocytic-lymphohistiocytosis-hlh\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemophagocytic-lymphohistiocytosis-hlh":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,71,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641447","phase-2-naive-t-cell-deplete-grafts-for-gvhd-prevention-in-non-malignant-diseases-100641447",false,"NCT07660783","Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases","A Phase II Prospective Study Evaluating Selective Depletion of CD45RA+ (Naïve) T Cells (TND) From Peripheral Blood Stem Cell (PBSC) Grafts for Prevention of Graft Versus Host Disease (GVHD) in Non-Malignant Diseases (NMDs)","Inclusion Criteria:\n\n* Considered appropriate candidate for allogeneic HCT following low dose (4Gy) TBI containing-conditioning and have one of the following diagnoses: A) BMF B)Hemoglobinopathies C)PID D) Autoimmune cytopenias E) Immune dysregulation F) HLH G) Other NMD treatable by HCT and NMD that is not clearly defined (a patient with a NMD for whom genetic testing has been done and a genetic mutation responsible for their NMD phenotype has not been identified) are eligible for the study following discussion with and approval by the protocol PI\n* Patients aged 6 months- 5 years old (inclusive) at the time of informed consent\n* Patient with suitable HCT donor (see inclusion criteria below)\n* Recipient informed consent\u002Fassent (13 years and older), and\u002For legal guardian permission must be obtained\n\nExclusion Criteria:\n\n* Patient with aplastic anemia\n* Patients with severe combined immunodeficiency (SCID)\n* Fanconi anemia\n* Dyskeratosis congenita\n* Patient weight \\> 100 kg\n* Patients who are positive for HIV-1, HIV-2\n* Patients with current neoplastic disorders\n* Patients with uncontrolled infections for whom HCT is considered contraindicated by the consulting infectious disease physician.\n* Patients with organ dysfunction including A) Renal insufficiency B) Impaired cardiac function C)Impaired pulmonary function D) Liver dysfunction\n* Patients who are pregnant or breast-feeding\n* Patients on other experimental protocols for prevention of GVHD\n* Patients of childbearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during and for 12 months post-HCT\n* Patients with any other significant medical conditions that would make them unsuitable for transplantation, as determined by the PI\n* Patients with a known hypersensitivity to tacrolimus or MMF","ALL","6 Months","50 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.",[27,28,29,30,31,32,33],"Bone Marrow Failure","Hemoglobinopathies","Primary Immune Deficiency (PID)","Autoimmune Cytopenia","Immune Dysregulation","Hemophagocytic Lymphohistiocytosis (HLH)","Non Malignant Disorders","NOT_YET_RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2035-09",{"name":44,"class":45},"Fred Hutchinson Cancer Center","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100641036","phase-2-all-trans-retinoic-acid-for-the-treatment-of-hemophagocytic-lymphohistiocytosis-100641036","NCT07626398","All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis","An Open-Label Study Evaluating the Safety and Efficacy of All-Trans Retinoic Acid in Patients With Hemophagocytic Lymphohistiocytosis","* Inclusion Criteria\n\n  1. Age ≥18 years.\n  2. Patients diagnosed with active hemophagocytic lymphohistiocytosis according to HLH-2004 diagnostic criteria or the investigator's clinical assessment.\n  3. Newly diagnosed or treatment-naïve active HLH requiring initial HLH-directed therapy.\n  4. Presence of active disease manifestations, including at least one of the following: persistent fever, cytopenia, hyperferritinemia, splenomegaly, hypofibrinogenemia and\u002For hypertriglyceridemia, elevated soluble CD25, hemophagocytosis, reduced or absent NK-cell activity, or other HLH-related organ involvement.\n  5. Eastern Cooperative Oncology Group performance status of 0-3, or performance status considered acceptable by the investigator in the context of active HLH.\n  6. Adequate ability to receive oral medication, or ability to receive ATRA through an appropriate enteral route.\n  7. Expected survival of more than 48 hours in the judgment of the investigator.\n  8. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use effective contraception during treatment and for an appropriate period after the last dose of ATRA.\n  9. Ability to understand and willingness to sign written informed consent. For patients unable to provide consent because of disease severity, consent may be provided by a legally authorized representative according to local regulations.\n* Exclusion Criteria\n\n  1. Prior systemic HLH-directed therapy for the current HLH episode, including etoposide-based therapy, ruxolitinib, emapalumab, alemtuzumab, PD-1 blockade, or other investigational HLH-directed treatment. Short-term corticosteroids, supportive care, anti-infective therapy, or emergency treatment before enrollment may be allowed at the investigator's discretion.\n  2. Known hypersensitivity to all-trans retinoic acid, tretinoin, retinoids, or any component of the study drug.\n  3. Pregnant or breastfeeding women.\n  4. Patients with acute promyelocytic leukemia or other diseases for which ATRA is being used as standard leukemia-directed therapy.\n  5. Severe uncontrolled infection, shock, respiratory failure, bleeding, or organ failure that, in the investigator's judgment, would make participation unsafe or prevent assessment of study treatment.\n  6. Severe hepatic dysfunction not primarily attributed to HLH, such as total bilirubin or transaminase levels considered unsafe for ATRA administration by the investigator.\n  7. Severe renal dysfunction requiring dialysis before enrollment, unless considered related to HLH and acceptable by the investigator.\n  8. Active intracranial hypertension, pseudotumor cerebri, or uncontrolled severe neurologic disease that may increase the risk of ATRA-related toxicity.\n  9. Uncontrolled hypertriglyceridemia or other metabolic abnormality that, in the investigator's judgment, would make ATRA treatment unsafe.\n  10. Concomitant use of vitamin A supplements, other systemic retinoids, or medications with unacceptable interaction risk that cannot be discontinued.\n  11. Any other condition that, in the investigator's judgment, would interfere with patient safety, protocol compliance, or interpretation of study results.","18 Years","65 Years",{"count":57,"type":21},30,[24,59],"PHASE3","This study is designed to evaluate the safety and preliminary efficacy of all-trans retinoic acid (ATRA) as an initial treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). HLH is a severe hyperinflammatory syndrome caused by excessive activation of immune cells and uncontrolled cytokine release. Current treatment often requires intensive immunosuppressive or cytotoxic therapy, which may be associated with significant toxicity.\n\nATRA is an orally available agent that has been widely used in other hematologic diseases and has immunomodulatory effects. Preclinical studies suggest that ATRA may help control HLH-related inflammation and improve immune dysregulation. In this study, patients with newly diagnosed or treatment-naïve active HLH will receive ATRA-based initial therapy. The study will assess clinical response, changes in HLH-related inflammatory markers, organ function, viral or disease-related parameters when applicable, and treatment-related adverse events.\n\nThe goal of this study is to determine whether ATRA can provide a safe and feasible initial therapeutic approach for active HLH and support further clinical development of ATRA-based treatment strategies in this disease.",[32],"2026-06-02",{"date":64,"type":38},"2026-06-04",{"date":66,"type":21},"2026-06-01",{"date":68,"type":21},"2029-06-01",{"name":70,"class":45},"Beijing Anzhen Hospital",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100633344","phase-1-combination-of-mitoxantrone-liposome-and-etoposide-dexamethasone-pegaspargase-and-golidocitinib-mepl-g-in-the-treatment-of-nkt-cell-lymphoma-associated-hemophagocytic-lymphohistiocytosis-nktcl-hlh-100633344","NCT07525466","Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK\u002FT-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)","Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK\u002FT-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH): a Prospective, Multi-center, Single Arm, Phase Ib\u002FII Clinical Trial","Inclusion Criteria:\n\n* Histologically confirmed extranodal NK\u002FT-cell lymphoma.\n* Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria).\n* Age ≥ 18 years, regardless of gender.\n* Negative HIV antigen or antibody.\n* Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac echocardiography.\n* No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral).\n* No uncontrolled infection (e.g., pulmonary infection, intestinal infection).\n* Negative HCV antibody; or positive HCV antibody with negative HCV RNA.\n* Negative HBsAg and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be \\\u003C 1×10³ copies\u002FmL to be eligible.\n* Signed written informed consent and ability to understand and comply with all study requirements.\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) cardiac function class ≥ II;\n* Female patients who are pregnant or breastfeeding;\n* Known hypersensitivity to any of the study drugs;\n* Presence of other concurrent malignancies (except non-melanoma skin cancer);\n* Concurrent central nervous system lymphoma infiltration;\n* Severe psychiatric disorders or inability to comply with follow-up;\n* Severe renal dysfunction (glomerular filtration rate \\\u003C 15 mL\u002Fmin);\n* Severe liver cirrhosis (MELD score \\> 20);\n* History of acute or chronic pancreatitis;\n* Simultaneous participation in another clinical trial.",{"count":79,"type":21},25,[81,24],"PHASE1","Extranodal NK\u002FT-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival \\\u003C2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance.\n\nThe JAK\u002FSTAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects.\n\nThis study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.",[84,32],"Extranodal NK T Cell Lymphoma",[86,87,88,89,90],"extranodal NK\u002FT-cell lymphoma","hemophagocytic lymphohistiocytosis","Mitoxantrone Liposome","Golidocitinib","JAK1","RECRUITING","2026-04-07",{"date":94,"type":38},"2026-04-13",{"date":96,"type":38},"2026-04-01",{"date":98,"type":21},"2028-09-30",{"name":100,"class":45},"Beijing Tongren Hospital",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":101},"100589250","phase-2-dose-modified-emapalumab-and-ruxolitinib-e-ru-regimens-for-hemophagocytic-lymphohistiocytosis-100589250","NCT06951971","Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis","A Multiple Center, Prospective, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of Dose-modified Emapalumab and Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n1. Fulfillment of at least five of the eight HLH-2004 criteria for HLH;\n2. Age 1-70 years old;\n3. No prior chemotherapy for HLH;\n4. Confirmed not pregnant and willing to use effective contraceptive measures during the study period, with the last dose of medication administered at least 12 months prior;\n5. Signed informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. According to the New York Heart Association (NYHA) score, patients with heart disease of grade II or above (including grade II);\n2. HIV-infected patients;\n3. Patients with severe renal dysfunction (glomerular filtration rate \\\u003C15 mL\u002Fmin);\n4. Patients with severe liver cirrhosis (MELD score\\>20);\n5. Uncontrollable infections (including lung infections, intestinal infections, etc.);\n6. Have serious mental illness;\n7. Have a history of active tumor;\n8. Participate in other clinical investigators at the same time;\n9. People with central nervous system involvement;\n10. Exclusion criteria related to concomitant medication.","1 Year","70 Years",{"count":57,"type":21},[24,59],"This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.",[32],"2025-04-23",{"date":117,"type":38},"2025-04-30",{"date":119,"type":21},"2025-06-01",{"date":121,"type":21},"2028-06-01",{"name":123,"class":45},"The First Affiliated Hospital of Soochow University"]